Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Takeda Pharma (TKPYY)

Takeda Pharma (TKPYY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Takeda Pharma 1-1 Doshomachi 4-chome Chuo-ku Osaka M0 540-8645 JPN

www.takeda.com P: 816-6204-2111

Description:

Takeda Pharmaceutical Company Limited operates as a research-based pharmaceutical company, engaged in manufacturing, marketing, and importing/exporting pharmaceutical drugs. Takeda's core business comprise of ethical drugs and its portfolio includes lansoprazole for the treatment of peptic ulcers, leuprolide acetate for the treatment of prostate cancer and endometriosis, pioglitazone hydrocholoride for the treatment of diabetes, and candesartan cilexetil for the treatment of hypertension. The Company promotes enhancing R&D pipeline, while concentrating its management resources to the four core therapeutic areas: lifestyle-related diseases, oncology and urological diseases, central nervous system disease and gastroenterological diseases. It operates in two segments- Ethical drug business and Consumer healthcare business. Consumer healthcare business provides Alinamin (vitamin B1 derivative preparations, etc.), Benza (cold remedies). Takeda Pharmaceutical Company Limited is headquartered in Osaka, Japan.

Key Statistics

Overview:

Market Capitalization, $K 25,919,552
Shares Outstanding, K 1,562,360
Annual Sales, $ 15,935 M
Annual Net Income, $ 1,682 M
Last Quarter Sales, $ 3,865 M
Last Quarter Net Income, $ 434,430 K
60-Month Beta 0.42
% of Institutional Shareholders 0.19%

Growth:

1-Year Return -41.58%
3-Year Return -32.16%
5-Year Return -27.71%
5-Year Revenue Growth -15.43%
5-Year Earnings Growth -29.61%
5-Year Dividend Growth 0.00%

Per-Share Information:

Next Earnings Date 02/07/19
Earnings Per Share ttm 1.37
EPS Growth vs. Prev Qtr -11.59%
EPS Growth vs. Prev Year 32.61%
Annual Dividend Rate, $ 0.58
Annual Dividend Yield 3.44%
Most Recent Dividend 0.288 on 09/27/18
Next Ex-Dividends Date 09/27/18
Dividend Payable Date 12/13/18
Dividend Payout Ratio -21.79%

TKPYY Ratios

Ratio
Price/Earnings ttm 12.22
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % 11.35%
Return-on-Assets % 5.57%
Profit Margin % 10.56%
Debt/Equity 0.49
Price/Sales 1.64
Price/Cash Flow 7.52
Price/Book 1.36
Book Value/Share 0.00
Interest Coverage 7.80
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar